Methadone Induces the Expression of Hepatic Drug-Metabolizing Enzymes through the Activation of Pregnane X Receptor and Constitutive Androstane Receptor
- 11 June 2009
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 37 (9), 1887-1894
- https://doi.org/10.1124/dmd.109.027854
Abstract
Methadone (MD) is the most established substance abuse pharmacotherapy of choice for the management of heroin dependence. To date, drug-drug interactions involving MD have been characterized asymmetrically among existing reports, which describe how other drugs affect the metabolic or pharmacokinetic profiles of MD; however, limited information is available regarding the potential for MD to influence similar fates of coadministered drugs. Moreover, little to no mechanistic evidence has been explored. Here, we show that MD induces hepatic drug-metabolizing enzymes (DMEs) through the activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR). Real-time polymerase chain reaction analysis of human hepatocyte cultures revealed that MD induces the mRNA expression of CYP2B6, CYP3A4, UGT1A1, and multidrug resistance 1 in a concentration-related manner, with the maximal induction of CYP2B6 challenging that of the induction by rifampicin. Furthermore, MD-mediated induction of CYP2B6 and CYP3A4 proteins was observed in Western blot analysis. In cell-based reporter assays, MD significantly increased human (h) PXR-mediated CYP2B6 reporter activities but exhibited minimal effect on hCAR activation as a result of the constitutive activity of hCAR in HepG2 cells. Further studies revealed that treatment with MD resulted in significant nuclear accumulation of adenovirus/enhanced yellow fluorescent protein tagged-hCAR in human hepatocytes, which has been regarded as the initial step of CAR activation. Additional analysis of the two enantiomers of MD, R-(–)-MD (active) and S-(+)-MD (inactive), indicates the lack of stereoselectivity pertaining to MD-mediated DME induction. Overall, our results show that MD induces the hepatic expression of multiple DMEs by activating PXR- and CAR-mediated pathways.Keywords
This publication has 30 references indexed in Scilit:
- Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacology & Therapeutics, 2007
- Impact of CYP2B6 Polymorphism on Hepatic Efavirenz Metabolism in VitroPharmacogenomics, 2007
- Enantiomeric Metabolic Interactions and Stereoselective Human Methadone MetabolismThe Journal of pharmacology and experimental therapeutics, 2007
- Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 InducersJournal of Pharmacology and Experimental Therapeutics, 2006
- In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisininEuropean Journal of Clinical Investigation, 2006
- Differential Regulation of Hepatic CYP2B6 and CYP3A4 Genes by Constitutive Androstane Receptor but Not Pregnane X ReceptorThe Journal of pharmacology and experimental therapeutics, 2006
- Differential UGT1A1 Induction by Chrysin in Primary Human Hepatocytes and HepG2 CellsThe Journal of pharmacology and experimental therapeutics, 2005
- Retinoid X Receptor-α-Dependent Transactivation by a Naturally Occurring Structural Variant of Human Constitutive Androstane Receptor (NR1I3)Molecular Pharmacology, 2005
- The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 GeneOnline Journal of Public Health Informatics, 1999
- Clinical Pharmacokinetics of MethadoneActa Anaesthesiologica Scandinavica, 1982